GENITOURINARY CANCER
Maha H. Hussain, MB ChB
University of Michigan Comprehensive Cancer Center
Translates scientific discoveries into clinical advances
Acceptance Speech
- Maha H. Hussain, MB ChB, is the Cis Maisel Professor of Oncology and a
professor of medicine and urology at the University of Michigan. She serves
as the associate director for Clinical Research and co-leader of the Prostate
Cancer/GU Oncology Program at the University of Michigan Comprehensive Cancer Center (UMCCC). Her work and accomplishments include:
- Contributed to research that led to the FDA approval of docetaxel for the treatment of men with advanced prostate cancer
- As lead investigator, evaluated optimal schedules of androgen deprivation therapy for patients with newly diagnosted metastatic prostate cancer through an international collaborative trial
- Pioneered novel clinical trials in bladder and prostate cancer
- Guided national research through various leadership positions, including as co-chair of the Prostate Cancer subcommittee of SWOG GU committee, as a member and 2013 chair of the Integration Panel (IP) of US Army Medical Research and Materiel Command Prostate Cancer Research Program, and as a member of the NCI-Cancer Biomarker Study Section and the NCI´s prostate cancer task force
- Serves as an FDA consultant and has served as a member and chair of the FDA Oncology Drug Advisory Committee
- Served/serves on the editorial boards of several national and international specialty publications, including the Journal of Clinical Oncology and the American Journal of Translational Research
- Honored with the University of Michigan Medical School League of Research Excellence award and the 2012 Clinical & Health Services Research award
